These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
254 related articles for article (PubMed ID: 29782272)
1. [Duration and Timing of Initiation of Therapy With Platelet P2Y12 Inhibitors in the Treatment of Patients With Acute Coronary Syndrome]. SHalaev SV; Safiullina ZM Kardiologiia; 2018 Mar; (3):54-62. PubMed ID: 29782272 [TBL] [Abstract][Full Text] [Related]
2. A comparison of cangrelor, prasugrel, ticagrelor, and clopidogrel in patients undergoing percutaneous coronary intervention: A network meta-analysis. Westman PC; Lipinski MJ; Torguson R; Waksman R Cardiovasc Revasc Med; 2017 Mar; 18(2):79-85. PubMed ID: 28089137 [TBL] [Abstract][Full Text] [Related]
4. Efficacy of ex vivo autologous and in vivo platelet transfusion in the reversal of P2Y12 inhibition by clopidogrel, prasugrel, and ticagrelor: the APTITUDE study. O'Connor SA; Amour J; Mercadier A; Martin R; Kerneis M; Abtan J; Brugier D; Silvain J; Barthélémy O; Leprince P; Montalescot G; Collet JP; Circ Cardiovasc Interv; 2015 Nov; 8(11):e002786. PubMed ID: 26553698 [TBL] [Abstract][Full Text] [Related]
5. [Experience with Prasugrel in the Treatment of Patients with Acute Coronary Syndrome]. Staroverov II; Merkulova IA; Avetisyan EA Kardiologiia; 2019 Jun; 59(6):18-25. PubMed ID: 31242837 [TBL] [Abstract][Full Text] [Related]
6. Contemporary use of P2Y12-inhibitors in patients with acute coronary syndrome undergoing percutaneous coronary intervention in Austria: A prospective, multi-centre registry. Tscharre M; Egger F; Machata M; Rohla M; Michael N; Neumayr M; Zweiker R; Hajos J; Adlbrecht C; Suppan M; Helmreich W; Eber B; Huber K; Weiss TW PLoS One; 2017; 12(6):e0179349. PubMed ID: 28632784 [TBL] [Abstract][Full Text] [Related]
8. Dual antiplatelet therapy with prasugrel or ticagrelor versus clopidogrel in interventional cardiology. Clemmensen P; Dridi NP; Holmvang L Cardiovasc Drugs Ther; 2013 Jun; 27(3):239-45. PubMed ID: 23380983 [TBL] [Abstract][Full Text] [Related]
9. Assessment of P2Y12 inhibitor usage and switching in acute coronary syndrome patients undergoing percutaneous coronary revascularization. Kudaravalli M; Althouse AD; Marroquin OC; Khandhar SJ; Sharbaugh MS; Toma C; Conrad Smith AJ; Schindler JT; Lee JS; Mulukutla SR Int J Cardiol; 2016 Nov; 223():854-859. PubMed ID: 27592042 [TBL] [Abstract][Full Text] [Related]
10. Frequency and Reasons of Dual Antiplatelet Therapy Discontinuation and Switching of P2Y12 Inhibitors in Patients with Acute Coronary Syndrome Treated with Stent Implantation. Fuertes Ferre G; Caballero Jambrina I; Ruiz Aranjuelo A; Jimeno Sánchez J; Galache Osuna JG; Andrés Esteban EM; Casasnovas Lenguas JA; Diarte de Miguel JA Cardiology; 2019; 142(4):203-207. PubMed ID: 31266007 [TBL] [Abstract][Full Text] [Related]
11. Impact of clopidogrel and potent P2Y 12 -inhibitors on mortality and stroke in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: a systematic review and meta-analysis. Aradi D; Komócsi A; Vorobcsuk A; Serebruany VL Thromb Haemost; 2013 Jan; 109(1):93-101. PubMed ID: 23197191 [TBL] [Abstract][Full Text] [Related]
12. Prasugrel in the treatment of acute coronary syndrome. Spartalis M; Tzatzaki E; Spartalis E; Paschou SA; Athanasiou A; Iliopoulos DC; Siasos G; Voudris V Future Cardiol; 2020 Nov; 16(6):559-568. PubMed ID: 32390477 [TBL] [Abstract][Full Text] [Related]
13. Developments in Oral Antiplatelet Agents for the Treatment of Acute Coronary Syndromes: Clopidogrel, Prasugrel, and Ticagrelor. Roffman DS J Pharm Pract; 2016 Jun; 29(3):239-49. PubMed ID: 25660584 [TBL] [Abstract][Full Text] [Related]
14. Reviewing the controversy surrounding pre-treatment with P2Y12 inhibitors in acute coronary syndrome patients. Capodanno D; Angiolillo DJ Expert Rev Cardiovasc Ther; 2016 Jul; 14(7):811-20. PubMed ID: 26953527 [TBL] [Abstract][Full Text] [Related]
15. Prasugrel hydrochloride for the treatment of acute coronary syndromes. Lhermusier T; Waksman R Expert Opin Pharmacother; 2015 Mar; 16(4):585-96. PubMed ID: 25633751 [TBL] [Abstract][Full Text] [Related]
16. A randomised trial on platelet function-guided de-escalation of antiplatelet treatment in ACS patients undergoing PCI. Rationale and design of the Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment for Acute Coronary Syndromes (TROPICAL-ACS) Trial. Sibbing D; Aradi D; Jacobshagen C; Gross L; Trenk D; Geisler T; Orban M; Gori T; Hadamitzky M; Merkely B; Kiss RG; Komócsi A; Dézsi CA; Thalmeier A; Löw A; Holdt L; Teupser D; Ince H; Felix SB; Parma R; Malek L; Horstkotte J; Baylacher M; Schwinger R; Rieber J; Mudra H; Hausleiter J; Huber K; Neumann FJ; Koltowski L; Huczek Z; Mehilli J; Massberg S; Thromb Haemost; 2017 Jan; 117(1):188-195. PubMed ID: 27652610 [TBL] [Abstract][Full Text] [Related]
17. Randomized Comparison of Oral P2Y Hochholzer W; Kleiner P; Younas I; Valina CM; Löffelhardt N; Amann M; Bömicke T; Ferenc M; Hauschke D; Trenk D; Neumann FJ; Stratz C JACC Cardiovasc Interv; 2017 Jan; 10(2):121-129. PubMed ID: 28104204 [TBL] [Abstract][Full Text] [Related]
18. [Impact of novel P2Y12 receptor inhibitors on platelet reactivity in acute coronary syndrome patients undergoing percutaneous coronary intervention]. Chong Tou TJ; Liu PM; Wang JF; Sio Cham ZC; O U YF; Lei Sio ZW; Lei Put PZ; Lei Sok SM; Zhou SX; Wu W Zhonghua Xin Xue Guan Bing Za Zhi; 2016 Feb; 44(2):138-43. PubMed ID: 26926507 [TBL] [Abstract][Full Text] [Related]
19. Viewpoint: mismatch between the European and American guidelines on oral antiplatelet P2Y12 inhibitors after acute coronary syndromes. Serebruany VL; DiNicolantonio JJ Thromb Haemost; 2013 Jul; 110(1):5-10. PubMed ID: 23743577 [TBL] [Abstract][Full Text] [Related]